Sai Life Sciences’ pharmaceutical API manufacturing site receives Certificate of Inspection from PMDA, Japan
HYDERABAD, India, Dec. 1, 2021 /PRNewswire/ -- Sai Life Sciences, a leading global Contract Research, Development & Manufacturing Organization (CRO/ CDMO), today announced that the Japanese regulatory agency, Pharmaceuticals and Medical Devices Agency (PMDA) completed a paper-based compliance inspection of its intermediate & API manufacturing facility in Bidar, India and issued a Certificate of...
OTSAW Technology Solutions and Swisslog Healthcare form joint venture to further develop Automated Guided Vehicles technology for the healthcare sector
SINGAPORE, Dec. 1, 2021 /PRNewswire/ -- Automated guided vehicles (AGVs) for clinical and non-clinical material handling have been used in hospitals for many years with increasing demand. Swisslog Healthcare is an established partner for AGVs in the hospital environment, with 580 installed systems and comprehensive service and implementation offerings in EMEA and APAC markets. ...
Silexon Partners with Excelra, Deploying GOSTAR to Strengthen its AI-driven Drug Discovery and Biopharmaceutical Research Platform
HYDERABAD, India and NANJING, China, Dec. 1, 2021 /PRNewswire/ -- Excelra, a leading global data & analytics provider, today announced its partnership with Silexon AI Technology, a next-generation biotech company with a scalable AI/ML (Artificial Intelligence and Machine Learning) platform for drug discovery and biopharmaceutical research. Under the agreement, Excelra will provide...
Ascentage Pharma and Innovent Biologics Announce Approval for China’s First Third-Generation BCR-ABL TKI Olverembatinib, Marking a Clinical Breakthrough in the Treatment of Chronic Myeloid Leukemia
SUZHOU, China and ROCKVILLE, Md., Nov. 30, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, and Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major...
Everest Medicines and Providence Therapeutics Jointly Announce Vaccine Development Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant
SHANGHAI and CALGARY, Canada, Dec. 1, 2021 /PRNewswire/ -- Everest Medicines and Providence Therapeutics ("Providence") jointly announced today that the companies have started working on a new version of COVID-19 vaccine specifically targeting the new Omicron variant. Scientists from the two companies have analyzed the sequence of the SARS-CoV-2 Omicron variant, selected viral sequences, and designed plasmid clones....
Innovent Biologics and Ascentage Pharma Announce the China NMPA Approval for China’s First Third-Generation BCR-ABL Inhibitor Olverembatinib for the Treatment of Chronic Myeloid Leukemia
SUZHOU, China, SAN FRANCISCO and ROCKVILLE, Md., Dec. 1, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, and Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),...
Lynk Pharmaceuticals Announced First Patient Dosed in Phase II Clinical Study of LNK01001
HANGZHOU, China, Dec. 1, 2021 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced the company has dosed the first patient with LNK01001 in its Phase II clinical trial in subjects with rheumatoid arthritis (RA). LNK01001 is a targeted inhibitor for the treatment of autoimmune diseases. The clinical study...
EpiVax Progresses on a Vaccine to Address SARS-CoV-2 Variants
PROVIDENCE, R.I., Dec. 1, 2021 /PRNewswire/ -- Today EpiVax, Inc. ("EpiVax") confirmed that the company's EPV-CoV-19 vaccine epitopes are 98.2% conserved in the new Omicron SARS-CoV-2 variant. EpiVax and EpiVax Therapeutics, Inc. ("EVT") are also affirming commitment to move the novel T cell epitope vaccine into the clinic in 2022. EPV-CoV-19 is...
Insilico Medicine Initiates First-in-Human Study of ISM001-055, a Novel Drug Discovered Using Insilico’s Proprietary End-to-end Artificial Intelligence Platform
NEW YORK and HONG KONG, Dec. 1, 2021 /PRNewswire/ -- Insilico Medicine, an end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that the first healthy volunteer has been dosed in a first-in-human microdose trial of ISM001-055. Insilico Medicine Initiates First-in-Human Study of ISM001-055 ISM001-055 is a potentially first-in-class small molecule inhibitor of a novel biological...
Invetech Wins International Health Award at Australian Export Awards
MELBOURNE, Australia, Dec. 1, 2021 /PRNewswire/ -- Invetech, an end-to-end commercialization partner to world's foremost therapeutic and diagnostic companies, has won the Australian International Health Award at the 59th Australian Export Awards on 25 November. Australian Export Awards Ceremony host David Koch virtually presents the award to Andreas Knaack, President, Invetech. ...
